Cargando…
Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis
(1) Background: Anti-carbamylated protein (CarP) antibodies have been studied as novel markers to aid in the diagnosis and prognosis of rheumatoid arthritis. (2) Methods: A total of 265 samples were included in the evaluation, for which 98 had results for anti-cyclic citrullinated peptide (CCP), 86...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318554/ https://www.ncbi.nlm.nih.gov/pubmed/35885566 http://dx.doi.org/10.3390/diagnostics12071661 |
_version_ | 1784755321256804352 |
---|---|
author | Ricchiuti, Vincent Chun, Kelly Y. Yang, Jane M. Aure, Mary Ann Gomez, Luis Norman, Gary L. Mahler, Michael |
author_facet | Ricchiuti, Vincent Chun, Kelly Y. Yang, Jane M. Aure, Mary Ann Gomez, Luis Norman, Gary L. Mahler, Michael |
author_sort | Ricchiuti, Vincent |
collection | PubMed |
description | (1) Background: Anti-carbamylated protein (CarP) antibodies have been studied as novel markers to aid in the diagnosis and prognosis of rheumatoid arthritis. (2) Methods: A total of 265 samples were included in the evaluation, for which 98 had results for anti-cyclic citrullinated peptide (CCP), 86 for rheumatoid factor (RF), and 212 for 14-3-3 eta protein. Anti-CarP antibodies were measured using a fetal calf serum-based single-step assay (research use only, Inova Diagnostics, San Diego, CA). (3) Results: Anti-CarP antibodies were significantly higher and more frequent in anti-CCP3.1+ (p = 0.0025), RF+ (p = 0.0043) and 14-3-3 eta+ (p = 0.028) samples compared to the negative counterpart group. In addition, isolated anti-CarP positivity occurred in samples negative for anti-CCP3.1, RF, or 14-3-3 eta. When anti-CarP antibodies were compared to each of the RF, anti-CCP3.1, and 14-3-3 eta by receiver operating characteristic (ROC) analyses, the area under the curve (AUC) values of 0.71 (RF), 0.68 (anti-CCP3.1), and 0.59 (14-3-3 eta), respectively, demonstrated a moderate correlation. Using an UpSet plot, we determined that 10.6% of the samples with available results for anti-CCP3.1, RF, and anti-CarP showed triple positivity. (4) Conclusions: Anti-carbamylated protein (anti-CarP) antibodies can be detected in anti-CCP, RF and 14-3-3 eta-positive and -negative patients, potentially identifying specific subsets of patients. |
format | Online Article Text |
id | pubmed-9318554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93185542022-07-27 Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis Ricchiuti, Vincent Chun, Kelly Y. Yang, Jane M. Aure, Mary Ann Gomez, Luis Norman, Gary L. Mahler, Michael Diagnostics (Basel) Brief Report (1) Background: Anti-carbamylated protein (CarP) antibodies have been studied as novel markers to aid in the diagnosis and prognosis of rheumatoid arthritis. (2) Methods: A total of 265 samples were included in the evaluation, for which 98 had results for anti-cyclic citrullinated peptide (CCP), 86 for rheumatoid factor (RF), and 212 for 14-3-3 eta protein. Anti-CarP antibodies were measured using a fetal calf serum-based single-step assay (research use only, Inova Diagnostics, San Diego, CA). (3) Results: Anti-CarP antibodies were significantly higher and more frequent in anti-CCP3.1+ (p = 0.0025), RF+ (p = 0.0043) and 14-3-3 eta+ (p = 0.028) samples compared to the negative counterpart group. In addition, isolated anti-CarP positivity occurred in samples negative for anti-CCP3.1, RF, or 14-3-3 eta. When anti-CarP antibodies were compared to each of the RF, anti-CCP3.1, and 14-3-3 eta by receiver operating characteristic (ROC) analyses, the area under the curve (AUC) values of 0.71 (RF), 0.68 (anti-CCP3.1), and 0.59 (14-3-3 eta), respectively, demonstrated a moderate correlation. Using an UpSet plot, we determined that 10.6% of the samples with available results for anti-CCP3.1, RF, and anti-CarP showed triple positivity. (4) Conclusions: Anti-carbamylated protein (anti-CarP) antibodies can be detected in anti-CCP, RF and 14-3-3 eta-positive and -negative patients, potentially identifying specific subsets of patients. MDPI 2022-07-08 /pmc/articles/PMC9318554/ /pubmed/35885566 http://dx.doi.org/10.3390/diagnostics12071661 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Ricchiuti, Vincent Chun, Kelly Y. Yang, Jane M. Aure, Mary Ann Gomez, Luis Norman, Gary L. Mahler, Michael Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis |
title | Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis |
title_full | Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis |
title_fullStr | Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis |
title_full_unstemmed | Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis |
title_short | Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis |
title_sort | anti-carbamylated protein (anti-carp) antibodies in patients evaluated for suspected rheumatoid arthritis |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318554/ https://www.ncbi.nlm.nih.gov/pubmed/35885566 http://dx.doi.org/10.3390/diagnostics12071661 |
work_keys_str_mv | AT ricchiutivincent anticarbamylatedproteinanticarpantibodiesinpatientsevaluatedforsuspectedrheumatoidarthritis AT chunkellyy anticarbamylatedproteinanticarpantibodiesinpatientsevaluatedforsuspectedrheumatoidarthritis AT yangjanem anticarbamylatedproteinanticarpantibodiesinpatientsevaluatedforsuspectedrheumatoidarthritis AT auremaryann anticarbamylatedproteinanticarpantibodiesinpatientsevaluatedforsuspectedrheumatoidarthritis AT gomezluis anticarbamylatedproteinanticarpantibodiesinpatientsevaluatedforsuspectedrheumatoidarthritis AT normangaryl anticarbamylatedproteinanticarpantibodiesinpatientsevaluatedforsuspectedrheumatoidarthritis AT mahlermichael anticarbamylatedproteinanticarpantibodiesinpatientsevaluatedforsuspectedrheumatoidarthritis |